Search Within
Document Type
99-34-3
Applied Filters:
Keyword:'99-34-3'
Showing 1-30 of 520 results for "99-34-3" within Technical Documents
The Effective Use of Protein Kinase Inhibitors
82 61
48 75 38 99 86 8 6 54 66 10 83 105 106 103
99 98 103 104 101 67 95 77 101 95 82 99 67 96 90 76 93 63 98 105 83 69
The Effective Use of Protein Kinase Inhibitors
82 61
48 75 38 99 86 8 6 54 66 10 83 105 106 103
99 98 103 104 101 67 95 77 101 95 82 99 67 96 90 76 93 63 98 105 83 69
MILLIPLEX®MAP Human Myokine Panel is an optimized quantitative immunoassay that simultaneously measures 15 novel muscle-secreted factors
Musclin
Average
+std 3 100 96 105 71 90 95 109 95 97 105 119 84 100 82 106
+std 4 92 104 113 77 90 101 105 128 93 115 114 77 130 92 109
Data Sheet - P8375
.J.B., Wat. Res., 31(7),
1694-1700 (1997).
10. Wodzig, K.W. et al., Ann. Clin. Biochem.,
34(Pt 3), 263-268 (1997).
11. Bar-Nun, N. et al., FEMS. Microbiol. Lett.,
217(1), 121-124 (2002).
Quantitative PCR Product Listing
r
:
1
.
8
0
0
.
3
2
5
.
3
0
1
0
T
e
c
h
n
i
c
a
l
S
e
r
v
i
c
e
:
MOUSE ANTI-ECHOVIRUS BLEND MONOCLONAL ANTIBODY
LOT NUMBER:
QUANTITY: 100 μL
SPECIFICITY: Reacts with the Echovirus 4, 6, 9, 11, 30 and 34.
ISOTYPE: IgG
APPLICATIONS: IFA at 1:100.
Dilute with buffer pH 7.5-8.0 containing protein or
Spare parts for Mobius® FlexReady Solution with Smart Flexware® Assemblies For Chromatography and TFF
55
53
65
6359
58
34
54
30
57
33
15
14
3. Pump Cart & Pump
XMO1/2 & XMO3 & TF2S Pump Cart
MOUSE ANTI-HUMAN MEROSIN (M-CHAIN)
Genet. 99: 535-540.
8. Noam, I. et al. (1997) Neuromusc. Disord. 7: 176-179.
9. Tan, E. et al. (1997) Neuromusc. Disord. 7: 85-89.
10. Noam, I. et al. (1997) J.
Product Information Sheet - A1653
1× crystallized and lyophilized.
Prepared from A 1653 using method IV of
Cohn, et al.3
Powder
97-99% by agarose gel
A 8763
Prepared from A 1653.4
Powder
Essentially
Product Information Sheet - A6784
1× crystallized and lyophilized.
Prepared from A 1653 using method IV of
Cohn, et al.3
Powder
97-99% by agarose gel
A 8763
Prepared from A 1653.4
Powder
Essentially
Product Information Sheet - A9511
1× crystallized and lyophilized.
Prepared from A 1653 using method IV of
Cohn, et al.3
Powder
97-99% by agarose gel
A 8763
Prepared from A 1653.4
Powder
Essentially
Product Information Sheet - A3782
9511 1crystallized and lyophilized.
Prepared from A 1653 using method IV of
Cohn, et al.3
Powder
97-99% by agarose gel
A 8763 Prepared from A 1653.4 Powder
Essentially globulin free
A 3782
Product Information Sheet - A8763
1× crystallized and lyophilized.
Prepared from A 1653 using method IV of
Cohn, et al.3
Powder
97-99% by agarose gel
A 8763
Prepared from A 1653.4
Powder
Essentially
Product Information Sheet - A3173
1× crystallized and lyophilized.
Prepared from A 1653 using method IV of
Cohn, et al.3
Powder
97-99% by agarose gel
A 8763
Prepared from A 1653.4
Powder
Essentially
Product Information Sheet - A6909
1× crystallized and lyophilized.
Prepared from A 1653 using method IV of
Cohn, et al.3
Powder
97-99% by agarose gel
A 8763
Prepared from A 1653.4
Powder
Essentially
Product Information Sheet - A2817
1× crystallized and lyophilized.
Prepared from A 1653 using method IV of
Cohn, et al.3
Powder
97-99% by agarose gel
A 8763
Prepared from A 1653.4
Powder
Essentially
Product Information Sheet - A9080
1× crystallized and lyophilized.
Prepared from A 1653 using method IV of
Cohn, et al.3
Powder
97-99% by agarose gel
A 8763
Prepared from A 1653.4
Powder
Essentially
Product Information Sheet - A1887
1× crystallized and lyophilized.
Prepared from A 1653 using method IV of
Cohn, et al.3
Powder
97-99% by agarose gel
A 8763
Prepared from A 1653.4
Powder
Essentially
Product Information Sheet - A4327
1× crystallized and lyophilized.
Prepared from A 1653 using method IV of
Cohn, et al.3
Powder
97-99% by agarose gel
A 8763
Prepared from A 1653.4
Powder
Essentially
RiOs™ 30/50/100/150/200
%
ion rejection 95-99 % 95-99 % 95-99 % 95-99 % 95-99 %
Organic rejection
(MW > 200 Dalton)
> 99 % > 99 % > 99 % > 99 % > 99 %
Particles > 99 % >
Quality Control Range Sheet- MCKP1-102 and MCKP1-202
pg/ml
TIM-3 Control 1 46 - 95 pg/mL CD25/IL-2Rα Control1 21 - 44 pg/ml
Control 2 185 - 383 pg/mL Control 2 83
Data Sheet - D3939
regeneration using artificial
human skin models". University of New South
Wales, Ph.D. dissertation, p. 34 (2020).
27. Kaiser, Helen Elizabeth, "The role of kynurenine, a
tryptophan metabolite that increases
Product Information Sheet - A8056
1
2
34
5
A8056 Page 2 of 2
09/20/96 - MAC
3-AMINO-1,2,4-TRIAZOLE
Sigma Prod. No. A8056
REFERENCES:
1. Aldrich Chemical Co. Catalog, p. 97 (1996-1997).
2. M. C. DeTraglia
Product Information Sheet - B5144
assay.
Anal. Biochem., 143, 293-297 (1984).
3. Taussig, S. J., The mechanism of the
physiological action of bromelain. Med.
Hypotheses, 6, 99-104 (1980).
4. Livio, M., et al., Drugs. Exptl.
Product Information Sheet - B4882
Anal. Biochem., 143(2), 293-297 (1984).
3. Taussig, S.J., The mechanism of the physiological
action of bromelain. Medical Hypotheses, 6(1),
99-104 (1980).
4. Livio, M. et al., Drugs, Exptl
Data Sheet - A6561
Phosphatase antibody produced in mouse (A6561) - Datasheet
MONOCLONAL ANTI-BIOTIN
CLONE BN-34
Alkaline Phosphatase Conjugate
Immunoglobulin Fraction of Mouse Ascites Fluid
Product No. A
Validation and Qualification for Durapore® Sterilizing-Grade (0.22 µm) Membrane VMF4
4.21 95 61 15.0 >8.22 114
3 10.0 4.22 116 62 16.2 >8.22 94
1 10.2 4.29 117 63 16.0 8.22 96
21 10.2 4.30 118 7 13.6 >8.29 106
20 10.3 4.35 113 10 14.1
Data Sheet - 76307
An irreversible serine protease inhibitor, BioPharm, 6, 34 (1993).
2. Lunn, G. and Sansone, E.B., Appl. Biochem. Biotechnol., 48, 57 (1994).
3. Markwardt, F. et al., Thrombosis Research, 2, 343 (1973
Aldrich Polymer Products Application - Electronics
Biphenylyl)-5-(4-tert-butylphenyl)-1,3,4-oxadiazole, 99+% (PBD) .5g
44,326-3 N,N’-Bis(3-methylphenyl)-N,N’-diphenylbenzidine, 99% (TPD) 1g ; 5g
45,976-3 Tri-p-tolylamine, 97% ............................
Data Sheet - P8833
2. Lee, Y.S., and Wurster, R.D., Cancer Lett., 93, 157-
163 (1995).
3. Manabe I. And Owens, G.K., Circ. Res., 88, 1127-
34 (2001).
4. Marchetti S., et al., J. Cell Sci., 115, 2075-85
(2002).
Page 1 of 18